HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BIBW 2669

a radiation sensitizing agent and an ErbB2 tyrosine kinase inhibitor

Also Known As:

BIBW-2669; BIBW2669

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - BIBW 2669: 1

Experts

1.	Baumann, Michael: 1 article (05/2007)
2.	Dörfler, Annegret: 1 article (05/2007)
3.	Eicheler, Wolfgang: 1 article (05/2007)
4.	Hering, Sandra: 1 article (05/2007)
5.	Krause, Mechthild: 1 article (05/2007)
6.	Schütze, Christina: 1 article (05/2007)
7.	Solca, Flavio: 1 article (05/2007)
8.	Zips, Daniel: 1 article (05/2007)

Related Diseases

1.	Neoplasms (Cancer) 05/01/2007 - "Daily application of BIBW 2669 or BIBW 2992 after a single-dose irradiation showed a clear inhibition of tumor growth with a significantly longer tumor growth delay after drug treatment compared to control tumors (p < 0.002). " 05/01/2007 - "Daily oral application of BIBW 2669 or BIBW 2992 in mice bearing unirradiated FaDu tumors showed a marked antiproliferative effect with a significant prolongation of tumor growth delay (p < 0.0001). " 05/01/2007 - "Tumor volume and tumor growth delay (GD(V2)) were determined in tumors growing in NMRI (nu/nu) nude mice, treated with (a) BIBW 2992 (20 mg kg(-1) body weight orally), BIBW 2669 (3-4 mg kg(-1) body weight orally) or carrier until a final tumor diameter of 15 mm, or, (b) 3 days before a 20-Gy single-dose irradiation or, (c) after a 20-Gy single-dose irradiation until reaching the final tumor diameter. " 05/01/2007 - "To investigate the effect of the dual EGFR/HER2 (ErbB2) tyrosine kinase inhibitors BIBW 2992 and BIBW 2669 on proliferation and clonogenic cell survival of FaDu human squamous cell carcinoma in vitro, and on tumor growth after single-dose irradiation in nude mice. "
2.	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/01/2007 - "Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma." 05/01/2007 - "To investigate the effect of the dual EGFR/HER2 (ErbB2) tyrosine kinase inhibitors BIBW 2992 and BIBW 2669 on proliferation and clonogenic cell survival of FaDu human squamous cell carcinoma in vitro, and on tumor growth after single-dose irradiation in nude mice. "
3.	Body Weight (Weight, Body) 05/01/2007 - "Tumor volume and tumor growth delay (GD(V2)) were determined in tumors growing in NMRI (nu/nu) nude mice, treated with (a) BIBW 2992 (20 mg kg(-1) body weight orally), BIBW 2669 (3-4 mg kg(-1) body weight orally) or carrier until a final tumor diameter of 15 mm, or, (b) 3 days before a 20-Gy single-dose irradiation or, (c) after a 20-Gy single-dose irradiation until reaching the final tumor diameter. "

Related Drugs and Biologics

1.	Protein-Tyrosine Kinases (Tyrosine Kinase)
2.	Tyrosine Kinase Inhibitors
3.	Afatinib
4.	L 644711 (B-3(+))